Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561648 | 1.00 | MME (0.54) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL7123861 | 1.00 | MME (0.54) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL30416190 | 1.00 | MME (0.54) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL4560840 | 1.00 | MME (0.54) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL30452082 | 0.96 | MME (0.51) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL30552905 | 0.96 | MME (0.51) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL30337052 | 0.93 | MME (0.49) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL30433786 | 0.93 | MME (0.49) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL29354264 | 0.93 | MME (0.49) | MMETGFBR1NOD1PAX8ACE | |
| SCHEMBL26223895 | 0.91 | MME (0.47) | MMETGFBR1NOD1PAX8ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260140123-A1 | GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS | JULIUS MAXIMILIANS UNIV WUERZBURG (DE) | 2026-05-21 | — | — | US | claimed |
| US-12629418-B2 | Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2026-05-19 | — | — | US | claimed |
| WO-2026102031-A1 | PASYLATED URICASE VARIANTS AND METHODS OF USE THEREOF | INSMED INCORPORATED (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260070965-A1 | ANTI-GDF15 ANTIBODY FOR NEOADJUVANT THERAPY OF CANCER | CATALYM GMBH (DE) | 2026-03-12 | — | — | US | claimed |
| EP-4705321-A2 | SPYCATCHER ANALOGS AND USES THEREOF | Bio-Rad ABD Serotec GmbH (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20260055172-A1 | ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER | CataIYm GmbH (DE) | 2026-02-26 | — | — | US | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20220153848-A1 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | DRAGONFLY THERAPEUTICS, INC. | 2022-05-19 | — | — | US | claimed |
| WO-2022101263-A1 | ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER | CATALYM GMBH (DE) | 2022-05-19 | — | — | WO | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-20220119534-A1 | PROTEINS BINDING NKG2D, CD16 AND CLEC12A | DRAGONFLY THERAPEUTICS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-20220089760-A1 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE | DRAGONFLY THERAPEUTICS, INC. | 2022-03-24 | — | — | US | claimed |
| US-11262360-B2 | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2022-03-01 | — | — | US | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022031965-A1 | PROTEINS BINDING NKG2D, CD16 AND EGFR | DRAGONFLY THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055172-A1 | ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER | IL15, IL15RA, CD4 | MME 3255/4885TGFBR1 175/4885NOD1 3061/4885 |
| US-20260140123-A1 | GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS | IL15, PDCD1, PDCD1LG2 | MME 2613/4885TGFBR1 82/4885NOD1 2363/4885 |
| US-12629418-B2 | Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers | PDCD1, PDCD1LG2, CD274 | MME 2774/4885TGFBR1 222/4885NOD1 4281/4885 |
| US-20260070965-A1 | ANTI-GDF15 ANTIBODY FOR NEOADJUVANT THERAPY OF CANCER | IL15, IL15RA, ISG15 | MME 800/4885TGFBR1 403/4885NOD1 2001/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | MME 2476/4885TGFBR1 2127/4885NOD1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.